IL2 and neoplasm: Subsequently, they utilized a new type of anti‐CD25 antibodies, which have stronger binding abilities to activate FcγRs, and combined them with PD‐1 blockade to deplete Treg cells to obtain satisfactory anti‐tumor effects.[115] Furthermore, blocking the IL‐2 signal on effector T cells using anti‐CD25 antibodies can limit the effect of these antibodies.